Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 36

Sort by

Sort Order Select

Journal Articles

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Blood (2024) 144 (Supplement 1): 4617.

https://doi.org/10.1182/blood-2024-199577

Published: 2024

Journal Articles

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Blood (2024) 144 (Supplement 1): 4409.

https://doi.org/10.1182/blood-2024-198687

Published: 2024

Journal Articles

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Blood (2024) 144 (Supplement 1): 4408.

https://doi.org/10.1182/blood-2024-198056

Published: 2024

Journal Articles

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

Patrick Connor Johnson, Richard Newcomb, Jeremy S. Abramson, Ann S. LaCasce, Julia Rice, Daniel Yang, Bridget Coffey, Sruthi K. Venkatachalam, Netana H. Markovitz, Emilia Kaslow-Zieve, Oreofe O. Odejide, Areej El-Jawahri

Blood (2024) 144 (Supplement 1): 400.

https://doi.org/10.1182/blood-2024-205279

Published: 2024

Journal Articles

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Blood (2024) 144 (Supplement 1): 1669.

https://doi.org/10.1182/blood-2024-203414

Published: 2024

Journal Articles

Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers

Hari S. Raman, Scott Greenwald, Edo Banach, Gregory A Abel, Charlotta Lindvall, Oreofe O. Odejide

Blood (2024) 144 (Supplement 1): 792.

https://doi.org/10.1182/blood-2024-200990

Published: 2024

Journal Articles

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Netana Markovitz, Oreofe O. Odejide, Areej El-Jawahri, Patrick Connor Johnson

Blood (2023) 142 (Supplement 1): 2409.

https://doi.org/10.1182/blood-2023-187708

Published: 2023

Journal Articles

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

Blood (2023) 142 (Supplement 1): 3031.

https://doi.org/10.1182/blood-2023-173103

Published: 2023

Journal Articles

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Jennifer L Crombie, Austin I Kim, Nancy L. Bartlett, Robert A. Redd, Victoria Patterson, Celeste Carey, Sobana Balasubramanian, Oreofe O. Odejide, Reid W. Merryman, Ann LaCasce, Caron A Jacobson, Eric Jacobsen, Erin M Parry, David C Fisher, Alex F. Herrera, Matthew S Davids, Margaret A. Shipp, Philippe Armand, Geoffrey P. Shouse

Blood (2023) 142 (Supplement 1): 1735.

https://doi.org/10.1182/blood-2023-181067

Published: 2023

Journal Articles

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

Patrick Connor Johnson, Netana Markovitz, Richard Newcomb, Daniel Yang, Julia Rice, Bridget Coffey, Oreofe O. Odejide, Areej El-Jawahri

Blood (2023) 142 (Supplement 1): 4487.

https://doi.org/10.1182/blood-2023-187346

Published: 2023

Journal Articles

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Blood (2023) 142 (7): 621–628.

https://doi.org/10.1182/blood.2023020244

Published: 2023

Journal Articles

Anxiety and Depression Among Patients Newly Diagnosed with Lymphoma and Myeloma

Oreofe O. Odejide, Tamryn F. Gray, Tsotso Ablorh, Miryam Yusufov, Gregory A. Abel, Lizabeth Roemer

Blood (2022) 140 (Supplement 1): 8085–8086.

https://doi.org/10.1182/blood-2022-167288

Published: 2022

Journal Articles

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

Blood (2022) 140 (Supplement 1): 6531–6533.

https://doi.org/10.1182/blood-2022-159823

Published: 2022

Journal Articles

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Mwanasha H. Merrill, Parastoo B. Dahi, Robert A. Redd, Mikaela M. McDonough, Yi-Bin Chen, Ann S. LaCasce, David C. Fisher, Alex F. Herrera, Caron A. Jacobson, Austin I. Kim, Reid W Merryman, Oreofe O. Odejide, Samuel Ng, Yago Nieto, Craig S. Sauter, Gunjan L. Shah, Jasmine Zain, Philippe Armand, Eric D Jacobsen

Blood (2022) 140 (Supplement 1): 1185–1187.

https://doi.org/10.1182/blood-2022-164839

Published: 2022

Journal Articles

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Blood (2021) 138 (Supplement 1): 3491.

https://doi.org/10.1182/blood-2021-147263

Published: 2021

Journal Articles

Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies

Oreofe O. Odejide, Scott F. Huntington, Thomas M. Kuczmarski, Eleanor Shi, James A. Tulsky, Gregory A. Abel

Blood (2021) 138 (Supplement 1): 4026.

https://doi.org/10.1182/blood-2021-153361

Published: 2021

Journal Articles

Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study

Inna Gong, Matthew Cheung, Kelvin Chan, Sumedha Arya, Neil Faught, Ning Liu, Oreofe O. Odejide, Gregory A. Abel, Michael Raphael, Anca Prica, Christopher Booth, Thomas M. Kuczmarski, Lee Mozessohn

Blood (2021) 138 (Supplement 1): 1969.

https://doi.org/10.1182/blood-2021-149469

Published: 2021

Journal Articles

Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey

Oreofe O. Odejide, Scott F. Huntington, Eleanor Shi, Kimberly S. Johnson, James A. Tulsky, Gregory A. Abel

Blood (2021) 138 (Supplement 1): 3020.

https://doi.org/10.1182/blood-2021-153304

Published: 2021

Journal Articles

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma

Netana H. Markovitz, Alisha Yi, Oreofe O. Odejide, Richard Newcomb, Hermioni L. Amonoo, Ashley M. Nelson, Matthew J. Reynolds, Julia Rice, Mitchell W. Lavoie, Ryan D. Nipp, Areej El-Jawahri, Patrick Connor Connor Johnson

Blood (2021) 138 (Supplement 1): 5005.

https://doi.org/10.1182/blood-2021-146527

Published: 2021

Journal Articles

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-140965

Published: 2020

NARROW

Characteristics and Outcomes of Patients with Double Refractory (DR) or Double Exposed (DE) CLL

Long-Term Follow-up of Bendamustine/Rituximab - Rituximab/Cytarabine (BR/RC) Induction Therapy for Previously Untreated Transplant-Eligible Patients with Mantle Cell Lymphoma (MCL)

Preliminary Efficacy and Safety of a Phase 1/2 Study of Acalabrutinib, Venetoclax, and Obinutuzumab in Patients with Relapsed/Refractory and Previously Untreated Mantle Cell Lymphoma (MAVO)

Comparison between Vulnerable Elders Survey-13 and Comprehensive Geriatric Assessment in Predicting Clinical Outcomes in Aggressive Lymphomas

Ipilimumab with and without Nivolumab in Patients with Classic Hodgkin Lymphoma with Progression after PD-1 Blockade

Impact of Fee-for-Service Versus Managed Care Medicare Insurance on the Quality of End-of-Life Care Among Older Adults with Blood Cancers

Prognostic Understanding in Newly Diagnosed Older Adults with Diffuse Large B Cell Lymphoma (DLBCL) or DLBCL/High Grade B-Cell Lymphoma with MYC and BCL2 rearrangements

Phase I Safety and Preliminary Efficacy of Acalabrutinib, Venetoclax, and Obinutuzumab (AVO) in Patients with Relapsed/Refractory Mantle Cell Lymphoma

A Phase I Study of Copanlisib and Venetoclax in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Longitudinal Patient-Reported Outcomes and Clinical Outcomes By VES-13 and Comprehensive Geriatric Assessment in Older Adults with Aggressive Non-Hodgkin Lymphomas

A phase 2 study of pembrolizumab after autologous stem cell transplantation in patients with T-cell non-Hodgkin lymphoma

Anxiety and Depression Among Patients Newly Diagnosed with Lymphoma and Myeloma

Dual Immune Checkpoint Agents in Combination with Rituximab for Patients with Relapsed or Refractory Follicular Lymphoma

A Phase 2 Study of Pembrolizumab (MK-3475) after Autologous Stem Cell Transplantation in Patients with T-Cell Non-Hodgkin Lymphoma

Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation

Perceptions of Prognosis Among Patients with Advanced Hematologic Malignancies

Incidence of Mental Health Events and Its Association with Survival Among Patients with Diffuse Large B-Cell Lymphoma: A Population-Based Cohort Study

Perceptions of Hospice and Transfusion Access Among Patients with Advanced Blood Cancers: Results from a Best-Worst Scaling Survey

End-of-Life Care for Older Adults with Aggressive Non-Hodgkin Lymphoma

Prognostic Value of Circulating Tumor DNA (ctDNA) in Autologous Stem Cell Graft and Post-Transplant Plasma Samples Among Patients with Diffuse Large B-Cell Lymphoma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only